Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Linezolid + Rifampicin for Infective Endocarditis
jRCTs031250254Recruiting
- Sponsor
- University of Tsukuba Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of linezolid and rifampicin in endocarditis (IE) (2 arms), sponsored by University of Tsukuba Hospital. Primary endpoint: Composite clinical outcome at 6 months after completion of oral therapy. Started Mar 2026; status: recruiting.
02
Drugs
linezolidrifampicin
03
Conditions
endocarditis (IE)
Beyond the preview
Go deeper on jRCTs031250254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250254.